Clinical reference Biomarker Directory
Back to directory

Carcinoembryonic antigen

Established

CEA is a standard tumor marker for colorectal cancer surveillance, always used alongside imaging and colonoscopy.

Also known as CEA carcinoembryonic antigen
In plain language

CEA is a blood test tracked regularly after colorectal cancer treatment to help catch a recurrence early. It's never used alone — it's combined with scans and colonoscopy, and unfortunately patients and providers are more likely to skip this test than the others.

Biomarker & context

Carcinoembryonic antigen (CEA) is an oncofetal glycoprotein overexpressed by approximately 85% of colorectal cancers and several other tumor types, serving as a standard biomarker for colorectal cancer monitoring.

What it indicates

CEA lacks the specificity and sensitivity needed for cancer screening but is valuable for baseline evaluation, treatment response monitoring, and recurrence surveillance in colorectal, appendiceal, pancreatic, and biliary cancers, plus medullary thyroid carcinoma and non-small cell lung cancer.

Diagnosis & clinical testing

Current NCCN 2025 guidelines recommend CEA monitoring every 3-6 months for 2 years, then every 6 months through year 5, for resected stage II-III colorectal cancer, always paired with imaging and colonoscopy rather than used alone. A Cochrane review found CEA alone insufficiently sensitive for detecting recurrence, recommending the highest assessed cutoff (10 μg/L) and combination with another surveillance modality.

Guiding treatment

Rising CEA during surveillance triggers further workup (imaging) for possible recurrence; a real-world caveat is that guideline adherence to CEA surveillance is consistently the weakest link compared to imaging and colonoscopy compliance in adherence studies.

Clinical significance

Surveillance compliance for CEA testing is consistently lower than for imaging or colonoscopy in real-world adherence studies.

References
  1. ASCO. (2020). Recommendations for Tumor Markers in Gastrointestinal Cancer.
  2. PMC. (2025). Personalized surveillance in colorectal cancer: NCCN 2025 guidelines.